Date:2/19/2013

inancing, the use of debt to fund acquisitions, developments and other investments, and the ability to refinance indebtedness as it comes due; failure to maintain the company's investment grade credit ratings with the ratings agencies; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; reductions in asset valuations and related impairment charges; risks and uncertainties affecting property development and construction; risks associated with downturns in foreign, domestic and local economies, changes in interest rates and foreign currency exchange rates, and volatility in the securities markets; ownership of properties outside of the United States that subject the company to different and potentially greater risks than those associated with the company's domestic operations; risks associated with the company's investments in loans, including borrower defaults and potential principal losses; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

'/>"/>

SOURCE BioMed Realty Trust, Inc. Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. ProGaming Platforms Corp. Executes Share Swap Agreement With BioMedix Ltd.
2. FDA Grants 510(k) clearance for new Fluke Biomedical ESA615 Electrical Safety Analyzer
3. BioMed Realty Trust Provides Notice of Redemption of 7.375% Series A Cumulative Redeemable Preferred Stock
4. Fluke Biomedical launches simple, portable, efficient VT305 Gas Flow Analyzer
5. Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Abiomed, Inc.
6. Robbins Umeda LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Abiomed, Inc.
7. Nelson Laboratories to Present Cleaning Validation Guidelines at BIOMEDevice San Jose
8. Saladax Biomedical, Inc. Appoints Mark D. Myslinski as Chief Commercial Officer
9. EastBridge Investment Group Announces Merger with Cellular Biomedicine Group
10. BioMed Realty To Audio Webcast Company Presentation At Investor Day 2012
11. KalVista Pharmaceuticals Wins £2.4m Biomedical Catalyst Grant to Further Develop Oral Plasma Kallikrein Inhibitors as a Treatment for Diabetic Macular Edema